We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dronedarone: A New Therapeutic Alternative for Cardiac Arrhythmias.
- Authors
Upaganlawar, A.; Gandhi, H.; Balaraman, R.
- Abstract
The article discusses the negative therapeutic properties of dronedarone, a drug from Sanofi-Aventis US LLC, in the U.S. Dronedarone was approved by the U.S. Food and Drug Administration (FDA) on July 2, 2009 and is a therapeutic agent for cardiac arrhythmia. The author noted that the drug was a useful option for patients requiring electroshock therapy. However, treatment was associated with an increased likelihood in deaths.
- Subjects
UNITED States; ARRHYTHMIA treatment; CARDIAC pacing; DRUG side effects; SANOFI-Aventis US LLC; UNITED States. Food &; Drug Administration
- Publication
Journal of Young Pharmacists, 2010, Vol 2, Issue 4, p430
- ISSN
0975-1483
- Publication type
Article
- DOI
10.4103/0975-1483.71620